Acute ischaemic stroke trials
- Reported quantity
- 30 mL per day by intravenous infusion
- Frequency
- Once daily
- Study duration
- 10–21 day courses
30 mL daily for 10 days is the most frequently repeated structure in the stroke literature.
Protocols · Cognitive
Cerebrolysin: literature-reported ranges
Cerebrolysin is a licensed medicine in a number of countries and has a large trial literature in stroke, traumatic brain injury and dementia. Its figures are stated in millilitres of a standard-concentration solution rather than in milligrams of an active substance.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- Porcine brain-derived peptide preparation
- Reported half-life
- Not defined — it is a mixture, not a single molecule
- Routes used in the literature
- Intravenous infusion and intramuscular in the trial literature
- Also written as
- —
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Alzheimer's disease trials
- Reported quantity
- 10–60 mL per day, most commonly 30 mL
- Frequency
- Five days per week
- Study duration
- 4-week courses, sometimes repeated
Course-based rather than continuous administration is standard in this literature.
Traumatic brain injury studies
- Reported quantity
- 30–50 mL per day
- Frequency
- Once daily
- Study duration
- 10–30 days
Cochrane reviews of this literature are notably cautious about effect size.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
Cerebrolysin · 60 mg Vial
Cerebrolysin is dosed at 20 mg–32 mg daily via subcutaneous injection in educational protocols. A 60 mg vial reconstituted with bacteriostatic water yields about 20 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → 20 mg/mL concentration.
- Typical daily range
- 20–32 mg once daily (gradual titration); split doses for >20 mg.
- Easy measuring
- At 20 mg/mL, 1 unit = 0.01 mL = 200 mcg (0.2 mg) on a U‑100 insulin syringe.
- Storage
- Lyophilized at room temperature ≤25 °C (≤77 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days; do not freeze.
Standard / Gradual Approach (3 mL = 20 mg/mL)
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 20 mg (20,000 mcg) | 100 units (1.0 mL) × 1 |
| Week 2 | 24 mg (24,000 mcg) | 60 units (0.6 mL) AM + 60 units (0.6 mL) PM |
| Week 3 | 28 mg (28,000 mcg) | 70 units (0.7 mL) AM + 70 units (0.7 mL) PM |
| Week 4+ | 32 mg (32,000 mcg) | 80 units (0.8 mL) AM + 80 units (0.8 mL) PM |
Reconstitution maths
Supplied as a ready-made ampoule solution (215.2 mg/mL of peptide preparation), not a powder. Nothing is reconstituted.
Open the reconstitution calculatorHow to read these figures
- It is a biological mixture — batch-to-batch composition is inherently less defined than a synthetic peptide.
- Meta-analyses of the stroke and TBI data are considerably less positive than individual trials.
- Porcine origin carries its own regulatory and acceptability considerations.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
- [1]Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin
Alvarez XA, et al. · Eur J Neurol · 2011 · DOI 10.1111/j.1468-1331.2010.03092.x
Alzheimer's disease patients received intravenous Cerebrolysin at three dosages (e.g., 10, 30, or 60 mL) administered over defined infusion cycles in a randomized double-blind trial.
View the record - [2]A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease
Panisset M, Gauthier S, Moessler H, Windisch M · J Neural Transm · 2005 · PMID 16420392
279 Alzheimer's disease patients received intravenous Cerebrolysin at 10 mL, 30 mL, or 60 mL doses, administered daily for treatment cycles over 24 weeks.
View the record - [3]Cerebrolysin and Recovery After Stroke (CARS)
Muresanu DF, Heiss WD, Hoemberg V, et al. (CARS study group) · Stroke · 2016 · PMC4689177
Stroke patients received intravenous Cerebrolysin 30 mL daily for 21 days, assessed for effects on upper-extremity motor recovery at day 90 versus placebo.
View the record
Search the databases yourself
Read the Cerebrolysin research briefOther cognitive compounds
DihexaAngiotensin IV analogue, HGF/c-Met potentiatorDSIPNonapeptidePE-22-28Spadin analogue, TREK-1 channel blockerPinealonSynthetic tripeptide (Glu-Asp-Arg) bioregulator
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.